Development Contract for a Two-Year Period
PORTLAND, Ore., Oct. 3 /PRNewswire-FirstCall/ -- Bioject Medical
Technologies Inc. (Nasdaq: BJCT), a leading developer of needle-free drug
delivery systems, announced today that it has received a Phase II Small
Business Innovation Research contract from the Centers for Disease Control
and Prevention ("CDC") for further development of a Disposable Cartridge
Jet Injection device (DCJI) for safer, needle-free global immunizations.
In 2005, the Company received Phase I funding for the initial prototype
system. In Phase I, the Company designed and built a spring-powered
prototype and proved its performance for intramuscular, subcutaneous and
intradermal injections. The Phase II funding is for a two-year period and
is for improvements in product design and the continued development of the
device and its unique single use auto-disable cartridge.
"We are pleased to have received the Phase II contract from the CDC for
the development of our immunization device with needle-free auto-disable
cartridges," said Jim O'Shea, Chairman, President and CEO of Bioject. "This
funding will allow us to continue to develop this new needle-free system,
targeting the growing immunization market in developed and developing
countries."
About Bioject
Bioject Medical Technologies Inc., based in Portland, Oregon, is an
innovative developer and manufacturer of needle-free drug delivery systems.
Needle-free injection works by forcing medication at high speed through a
tiny orifice held against the skin. This creates a fine stream of
high-pressure fluid penetrating the skin and depositing medication in the
tissue beneath. The Company is focused on developing mutually beneficial
agreements with leading pharmaceutical, biotechnology, and veterinary
companies.
For more information about Bioject, visit http://www.bioject.com .
SOURCE Bioject Medical Technologies Inc.
 back to top
Related links:
http://www.bioject.com/
CONTACT:
Jim O'Shea, Chief Executive Officer,
+1-503-692-8001, ext. 4161, or Chris Farrell, Vice President of
Finance, +1-503-692-8001, ext. 4132, both of Bioject Medical
Technologies Inc.
|
